{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:03:53Z","timestamp":1768565033254,"version":"3.49.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Immune checkpoint inhibitors against Programmed Cell Death Protein 1\/Programmed Cell (PD-1\/PD-L1) and CTLA-4\/B7 axes have had limited success in hematologic malignancies, requiring the need to explore alternative targets such as T-cell immunoreceptor with Ig and ITIM domains (TIGIT)\/CD155 to improve durable clinical responses. We undertook this study to investigate the expression profile of TIGIT such that the potential efficacy of TIGIT blockade could be mapped among lymphoma subtypes. We validated an immunohistochemical assay for TIGIT and evaluated its expression in lymphoma and tumor microenvironment (TME) cells in 661 lymphoma\/leukemia biopsies. Multiplex immunofluorescence was used for correlation with normal TME cell subsets. Tumor or TME TIGIT-positivity was defined as moderate to strong membrane staining in at least 10% of tumor or TME cells, respectively. TME TIGIT expression was correlated with overall survival and progression-free survival and comparison with PD-L1 expression. In most cases, lymphoma cells were TIGIT-negative except for angioimmunoblastic and peripheral T-cell lymphomas, which showed 91% and 47% positivity, respectively. A high proportion of small B-cell lymphoma and anaplastic large cell lymphoma cases had TIGIT-positive TME cells. Chronic lymphocytic leukemia\/small lymphocytic lymphoma patients with TIGIT-negative TME cells showed significantly shorter overall survival (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.04). No other statistically significant differences were found. When TIGIT was expressed in TME cells, there were a comparable number of TIGIT-positive only and dual TIGIT\/PD-L1 positive cases except for more TIGIT-positive only cases in CLL\/SLL. TIGIT expression shows distinctive profiles among lymphoma subtypes. Chronic lymphocytic leukemia\/small lymphocytic lymphoma and anaplastic large cell lymphoma demonstrated high TME TIGIT expression compared with PD-L1, with a high proportion of dual TIGIT and PD-L1-positivity. Our results are likely to contribute to the design and correlative study of therapeutic response in clinical trials targeting TIGIT alone or in combination with PD1\/PDL1.<\/jats:p>","DOI":"10.1097\/pas.0000000000002168","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T08:00:36Z","timestamp":1703664036000},"page":"337-352","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas"],"prefix":"10.1097","volume":"48","author":[{"given":"Diane","family":"Libert","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuchun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheren","family":"Younes","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia P.","family":"Mosquera","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[{"name":"Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiane","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Sao Paulo, Sao Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasodha","family":"Natkunam","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"8820377","DOI":"10.1155\/2020\/8820377","article-title":"Activating the antitumor immune response in non-Hodgkin lymphoma using immune checkpoint inhibitors","volume":"2020","author":"Joshi","year":"2020","journal-title":"J Immunol Res"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3892\/mmr.2021.12001","article-title":"A combination of PD-1\/PD-L1 inhibitors: the prospect of overcoming the weakness of tumor immunotherapy","volume":"23","author":"Kong","year":"2021","journal-title":"Mol Med Rep"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.imbio.2015.08.003","article-title":"TIGIT negatively regulates inflammation by altering macrophage phenotype","volume":"221","author":"Chen","year":"2016","journal-title":"Immunobiology"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1158\/1078-0432.CCR-20-0558","article-title":"TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma","volume":"26","author":"Yang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients","volume":"22","author":"Kong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum Pathol"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"e156254","DOI":"10.1172\/JCI156254","article-title":"Impaired TIGIT expression on B cells drives circulating follicular helper T cell expansion in multiple sclerosis","volume":"132","author":"Asashima","year":"2022","journal-title":"J Clin Invest"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/2326-6066.CIR-18-0351","article-title":"TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma","volume":"7","author":"Josefsson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"e1371399","DOI":"10.1080\/2162402X.2017.1371399","article-title":"TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia","volume":"7","author":"Catakovic","year":"2017","journal-title":"Oncoimmunology"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1038\/s41598-021-86655-8","article-title":"A novel scoring system for TIGIT expression in classic Hodgkin lymphoma","volume":"11","author":"Annibali","year":"2021","journal-title":"Sci Rep"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"D871","DOI":"10.1093\/nar\/gkm861","article-title":"The Stanford tissue microarray database","volume":"36","author":"Marinelli","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"1069378","DOI":"10.3389\/fonc.2022.1069378","article-title":"The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"R19-20250608"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/eji.201041136","article-title":"Vstm3 is a member of the CD28 family and an important modulator of T-cell function","volume":"41","author":"Levin","year":"2011","journal-title":"Eur J Immunol"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1073\/pnas.0903474106","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/eji.200839116","article-title":"A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC","volume":"39","author":"Boles","year":"2009","journal-title":"Eur J Immunol"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"1873607","DOI":"10.1080\/2162402X.2021.1873607","article-title":"Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 blockade augments human T cell adoptive cell transfer","volume":"10","author":"Martinez","year":"2021","journal-title":"Oncoimmunology"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J Clin Invest"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"12919","DOI":"10.3390\/ijms222312919","article-title":"Combined blockade of TIGIT and CD39 or A2AR enhances NK-92 Cell-mediated cytotoxicity in AML","volume":"22","author":"Brauneck","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3324\/haematol.2022.282177","article-title":"The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy","volume":"108","author":"Arruga","year":"2023","journal-title":"Haematologica"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"e1026530","DOI":"10.1080\/2162402X.2015.1026530","article-title":"Several immune escape patterns in non-Hodgkin\u2019s lymphomas","volume":"4","author":"Laurent","year":"2015","journal-title":"Oncoimmunology"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"103958","DOI":"10.1016\/j.cellimm.2019.103958","article-title":"TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia","volume":"344","author":"Zhang","year":"2019","journal-title":"Cell Immunol"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1186\/s12885-018-5111-1","article-title":"Expression of the immune checkpoint receptor TIGIT in Hodgkin\u2019s lymphoma","volume":"18","author":"Li","year":"2018","journal-title":"BMC Cancer"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","article-title":"Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"132","author":"Luchtel","year":"2018","journal-title":"Blood"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13046-017-0623-0","article-title":"STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC","volume":"36","author":"Han","year":"2017","journal-title":"J Exp Clin Cancer Res CR"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"e004984","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R40-20250608","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia\u2013lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"key":"R41-20250608","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T20:01:49Z","timestamp":1749412909000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002168"}},"subtitle":["Implications for Targeted Therapy"],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002168","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,22]]}}}